Financhill
Sell
45

ALEC Quote, Financials, Valuation and Earnings

Last price:
$1.43
Seasonality move :
-4.24%
Day range:
$1.39 - $1.46
52-week range:
$0.87 - $6.78
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.58x
P/B ratio:
1.50x
Volume:
638.2K
Avg. volume:
1.2M
1-year change:
-71.6%
Market cap:
$142M
Revenue:
$100.6M
EPS (TTM):
-$1.26

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ALEC
Alector
$4.3M -$0.46 -81.73% -17.5% $5.26
ENOV
Enovis
$558.9M $0.74 5.83% 1731.46% $56.50
GERN
Geron
$48.5M -$0.04 5212.1% -66.5% $3.69
MDGL
Madrigal Pharmaceuticals
$114.2M -$3.79 985.75% -48.55% $423.14
RYTM
Rhythm Pharmaceuticals
$40.2M -$0.68 50.34% -12.27% $83.42
UTHR
United Therapeutics
$729.3M $6.54 12.23% 25.78% $388.18
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ALEC
Alector
$1.42 $5.26 $142M -- $0.00 0% 1.58x
ENOV
Enovis
$32.57 $56.50 $1.9B -- $0.00 0% 0.85x
GERN
Geron
$1.45 $3.69 $923.5M -- $0.00 0% 8.25x
MDGL
Madrigal Pharmaceuticals
$270.87 $423.14 $6B -- $0.00 0% 18.60x
RYTM
Rhythm Pharmaceuticals
$59.59 $83.42 $3.8B -- $0.00 0% 26.87x
UTHR
United Therapeutics
$315.64 $388.18 $14.2B 12.60x $0.00 0% 5.09x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ALEC
Alector
9.09% -0.451 7.69% 3.23x
ENOV
Enovis
34.64% 1.134 63.52% 0.99x
GERN
Geron
30.68% 1.799 11.72% 6.84x
MDGL
Madrigal Pharmaceuticals
14.24% 1.767 1.61% 5.41x
RYTM
Rhythm Pharmaceuticals
-- 1.841 -- 2.97x
UTHR
United Therapeutics
2.85% 1.506 1.44% 5.05x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ALEC
Alector
-- -$44.7M -89.62% -92.15% -1216.52% -$60.8M
ENOV
Enovis
$332.2M -$42.9M -18.51% -26.77% -8.62% -$44.9M
GERN
Geron
$38.4M -$16.7M -35.11% -46.58% -29.38% -$48M
MDGL
Madrigal Pharmaceuticals
$132.7M -$79.3M -43.17% -49.57% -50.96% -$88.9M
RYTM
Rhythm Pharmaceuticals
$29.1M -$47M -116.92% -116.92% -134.57% -$40.4M
UTHR
United Therapeutics
$701.9M $382.8M 18.69% 19.92% 54.08% $386.3M

Alector vs. Competitors

  • Which has Higher Returns ALEC or ENOV?

    Enovis has a net margin of -1101.55% compared to Alector's net margin of -10.02%. Alector's return on equity of -92.15% beat Enovis's return on equity of -26.77%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    ENOV
    Enovis
    59.45% -$0.98 $4B
  • What do Analysts Say About ALEC or ENOV?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 227.57%. On the other hand Enovis has an analysts' consensus of $56.50 which suggests that it could grow by 73.47%. Given that Alector has higher upside potential than Enovis, analysts believe Alector is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    ENOV
    Enovis
    7 1 0
  • Is ALEC or ENOV More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Enovis has a beta of 1.583, suggesting its more volatile than the S&P 500 by 58.325%.

  • Which is a Better Dividend Stock ALEC or ENOV?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Enovis offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Enovis pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or ENOV?

    Alector quarterly revenues are $3.7M, which are smaller than Enovis quarterly revenues of $558.8M. Alector's net income of -$40.5M is higher than Enovis's net income of -$56M. Notably, Alector's price-to-earnings ratio is -- while Enovis's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.58x versus 0.85x for Enovis. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.58x -- $3.7M -$40.5M
    ENOV
    Enovis
    0.85x -- $558.8M -$56M
  • Which has Higher Returns ALEC or GERN?

    Geron has a net margin of -1101.55% compared to Alector's net margin of -50.09%. Alector's return on equity of -92.15% beat Geron's return on equity of -46.58%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    GERN
    Geron
    96.96% -$0.03 $387M
  • What do Analysts Say About ALEC or GERN?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 227.57%. On the other hand Geron has an analysts' consensus of $3.69 which suggests that it could grow by 154.31%. Given that Alector has higher upside potential than Geron, analysts believe Alector is more attractive than Geron.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    GERN
    Geron
    4 3 0
  • Is ALEC or GERN More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Geron has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.471%.

  • Which is a Better Dividend Stock ALEC or GERN?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Geron offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Geron pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or GERN?

    Alector quarterly revenues are $3.7M, which are smaller than Geron quarterly revenues of $39.6M. Alector's net income of -$40.5M is lower than Geron's net income of -$19.8M. Notably, Alector's price-to-earnings ratio is -- while Geron's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.58x versus 8.25x for Geron. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.58x -- $3.7M -$40.5M
    GERN
    Geron
    8.25x -- $39.6M -$19.8M
  • Which has Higher Returns ALEC or MDGL?

    Madrigal Pharmaceuticals has a net margin of -1101.55% compared to Alector's net margin of -53.36%. Alector's return on equity of -92.15% beat Madrigal Pharmaceuticals's return on equity of -49.57%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    MDGL
    Madrigal Pharmaceuticals
    96.71% -$3.32 $828.6M
  • What do Analysts Say About ALEC or MDGL?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 227.57%. On the other hand Madrigal Pharmaceuticals has an analysts' consensus of $423.14 which suggests that it could grow by 56.22%. Given that Alector has higher upside potential than Madrigal Pharmaceuticals, analysts believe Alector is more attractive than Madrigal Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    MDGL
    Madrigal Pharmaceuticals
    10 1 0
  • Is ALEC or MDGL More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Madrigal Pharmaceuticals has a beta of -0.906, suggesting its less volatile than the S&P 500 by 190.598%.

  • Which is a Better Dividend Stock ALEC or MDGL?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Madrigal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Madrigal Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or MDGL?

    Alector quarterly revenues are $3.7M, which are smaller than Madrigal Pharmaceuticals quarterly revenues of $137.3M. Alector's net income of -$40.5M is higher than Madrigal Pharmaceuticals's net income of -$73.2M. Notably, Alector's price-to-earnings ratio is -- while Madrigal Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.58x versus 18.60x for Madrigal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.58x -- $3.7M -$40.5M
    MDGL
    Madrigal Pharmaceuticals
    18.60x -- $137.3M -$73.2M
  • Which has Higher Returns ALEC or RYTM?

    Rhythm Pharmaceuticals has a net margin of -1101.55% compared to Alector's net margin of -151.35%. Alector's return on equity of -92.15% beat Rhythm Pharmaceuticals's return on equity of -116.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    RYTM
    Rhythm Pharmaceuticals
    88.85% -$0.81 $163.1M
  • What do Analysts Say About ALEC or RYTM?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 227.57%. On the other hand Rhythm Pharmaceuticals has an analysts' consensus of $83.42 which suggests that it could grow by 39.98%. Given that Alector has higher upside potential than Rhythm Pharmaceuticals, analysts believe Alector is more attractive than Rhythm Pharmaceuticals.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    RYTM
    Rhythm Pharmaceuticals
    8 0 0
  • Is ALEC or RYTM More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison Rhythm Pharmaceuticals has a beta of 2.362, suggesting its more volatile than the S&P 500 by 136.233%.

  • Which is a Better Dividend Stock ALEC or RYTM?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rhythm Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. Rhythm Pharmaceuticals pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or RYTM?

    Alector quarterly revenues are $3.7M, which are smaller than Rhythm Pharmaceuticals quarterly revenues of $32.7M. Alector's net income of -$40.5M is higher than Rhythm Pharmaceuticals's net income of -$49.5M. Notably, Alector's price-to-earnings ratio is -- while Rhythm Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.58x versus 26.87x for Rhythm Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.58x -- $3.7M -$40.5M
    RYTM
    Rhythm Pharmaceuticals
    26.87x -- $32.7M -$49.5M
  • Which has Higher Returns ALEC or UTHR?

    United Therapeutics has a net margin of -1101.55% compared to Alector's net margin of 40.56%. Alector's return on equity of -92.15% beat United Therapeutics's return on equity of 19.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    ALEC
    Alector
    -- -$0.41 $104.1M
    UTHR
    United Therapeutics
    88.36% $6.63 $7B
  • What do Analysts Say About ALEC or UTHR?

    Alector has a consensus price target of $5.26, signalling upside risk potential of 227.57%. On the other hand United Therapeutics has an analysts' consensus of $388.18 which suggests that it could grow by 22.98%. Given that Alector has higher upside potential than United Therapeutics, analysts believe Alector is more attractive than United Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    ALEC
    Alector
    5 1 1
    UTHR
    United Therapeutics
    6 6 0
  • Is ALEC or UTHR More Risky?

    Alector has a beta of 0.757, which suggesting that the stock is 24.33% less volatile than S&P 500. In comparison United Therapeutics has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.76%.

  • Which is a Better Dividend Stock ALEC or UTHR?

    Alector has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. United Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Alector pays -- of its earnings as a dividend. United Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ALEC or UTHR?

    Alector quarterly revenues are $3.7M, which are smaller than United Therapeutics quarterly revenues of $794.4M. Alector's net income of -$40.5M is lower than United Therapeutics's net income of $322.2M. Notably, Alector's price-to-earnings ratio is -- while United Therapeutics's PE ratio is 12.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Alector is 1.58x versus 5.09x for United Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ALEC
    Alector
    1.58x -- $3.7M -$40.5M
    UTHR
    United Therapeutics
    5.09x 12.60x $794.4M $322.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will Cameco Stock Be in 5 Years?
Where Will Cameco Stock Be in 5 Years?

Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…

Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth

Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…

Is Tesla Stock Overvalued or a Buy for the Next Decade?
Is Tesla Stock Overvalued or a Buy for the Next Decade?

Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…

Stock Ideas

Buy
67
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
68
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 46x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
73
CTEV alert for May 30

Claritev [CTEV] is up 34.96% over the past day.

Buy
69
ELF alert for May 30

e.l.f. Beauty [ELF] is up 23.68% over the past day.

Buy
67
BBW alert for May 30

Build-A-Bear Workshop [BBW] is up 21.83% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock